Jiang Hong, Yu Xin-Ming, Zhou Xing-Ming, Wang Xiao-Hong, Su Dan
Department of Thoracic Surgery, Key Laboratory of Thoracic Tumor Diagnosis (Esophagus, Lung) and Treatment Technology Research, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China ;
Exp Ther Med. 2013 May;5(5):1506-1510. doi: 10.3892/etm.2013.1007. Epub 2013 Mar 14.
The aim of this study was to explore the correlation between mRNA expression of β-tubulin-III and stathmin in patients with stage II non-small cell lung cancer (NSCLC) and the chemosensitivity to Navelbine plus cisplatin (NP), as well as to provide a basis for personalized treatment. A single-gene quantitative test was performed to detect the mRNA expression of β-tubulin-III and stathmin in the tumor tissue of patients with stage II NSCLC. All the patients underwent NP treatment following surgery and were followed-up to record their disease-free survival (DFS) and overall survival (OS). Statistical analyses were conducted to investigate the correlation between β-tubulin-III and stathmin mRNA expression and DFS and OS in the patients. β-tubulin-III mRNA expression was associated with OS in the 73 patients (P=0.003) and DFS was correlated with β-tubulin-III mRNA expression and lymphatic metastasis (P<0.01). Stathmin mRNA expression was not correlated with OS or DFS (P>0.05). OS and DFS were longer in the patients with low β-tubulin-III mRNA expression than in those with high β-tubulin-III mRNA expression (P<0.01); there was no significant change in OS and DFS between the patients with high and low mRNA expression of stathmin (P>0.05). The mRNA expression levels of β-tubulin-III in the tumor tissue of patients with stage II NSCLC may be considered as an index of prognosis and chemosensitivity, as well as a reference for personalized chemotherapeutic applications in patients.
本研究旨在探讨Ⅱ期非小细胞肺癌（NSCLC）患者β-微管蛋白Ⅲ（β-tubulin-III）和生存素（stathmin）的mRNA表达与长春瑞滨联合顺铂（NP）化疗敏感性之间的相关性，为个体化治疗提供依据。采用单基因定量检测法检测Ⅱ期NSCLC患者肿瘤组织中β-tubulin-III和stathmin的mRNA表达。所有患者术后均接受NP治疗，并进行随访，记录其无病生存期（DFS）和总生存期（OS）。进行统计学分析，以研究患者β-tubulin-III和stathmin mRNA表达与DFS和OS之间的相关性。73例患者中，β-tubulin-III mRNA表达与OS相关（P=0.003），DFS与β-tubulin-III mRNA表达及淋巴转移相关（P<0.01）。Stathmin mRNA表达与OS或DFS均无相关性（P>0.05）。β-tubulin-III mRNA表达低的患者OS和DFS较β-tubulin-III mRNA表达高的患者长（P<0.01）；stathmin mRNA表达高和低的患者之间OS和DFS无显著变化（P>0.05）。Ⅱ期NSCLC患者肿瘤组织中β-tubulin-III的mRNA表达水平可作为预后和化疗敏感性的指标，也可为患者个体化化疗应用提供参考。
